#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Asthma Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Leiomyosarcoma recurrent Malignant glioma Liposarcoma recurrent Renal cancer metastatic Breast angiosarcoma Turner's syndrome Rheumatoid arthritis Retinal dystrophy Cholestatic pruritus Synovitis Endometrial adenocarcinoma Stevens-Johnson syndrome Follicle centre lymphoma follicular grade I, II – III Adenomatous polyposis coli Ocular myasthenia More trials…

    Learn about Rare Diseases

    Phenylketonuria – Basic Information Rosai-Dorfman syndrome – Basic Information Extranodal marginal zone B-cell lymphoma (MALT type) – Basic Information Angiosarcoma recurrent – Diagnostics Lymphangiosarcoma Burkitt’s lymphoma – Basic Information Von Willebrand’s disease – Basic Information Vascular malformation – Trials in Disease Ewing’s sarcoma Combined immunodeficiency – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ucp2 Urapidil Rilpivirine Apitegromab Sabestomig ALLO-QUADCAR01-T Vitamin A Bp Acetazolamide Sodium X-396 LY3372993 Suvecaltamide Idarubicin Pertechnetate (99Mtc) Sodium Cls12311 Cobimetinib Ulipristal Acetate GRNA1599 4-Hydroxy-N-Desmethyltamoxifen Glpg3667 Fumarate Itolizumab More therapies…

    Learn about Your Condition

    Ataxia telangiectasia Coronary artery bypass Torticollis Glioma Cleft lip and palate Biliary cancer metastatic Nephrolithiasis Cerebellar ataxia Carotid artery stenosis Noonan syndrome Inflammatory bowel disease Oesophageal achalasia Anaemia of pregnancy Vitamin D deficiency Myocarditis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. NH Hospital a.s.

NH Hospital a.s.

K Nemocnici 1106/14, Horovice, 268 01, Czechia

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Elacestrant and Everolimus for Patients with Advanced ER+/HER2- Breast Cancer Resistant to Endocrine Therapy and CDK4/6 Inhibitors

    Recruiting

    3 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Goserelin Acetate
    • Triptorelin Acetate
    • Leuprorelin Acetate
    Austria Czechia France Germany Greece Italy +1

  • A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Exemestane
    • Tamoxifen Citrate
    • Triptorelin
    Austria Belgium Bulgaria Croatia Czechia Estonia +10

  • Study on the Effectiveness and Safety of Guselkumab and Ustekinumab for Patients with Moderate to Severe Crohn’s Disease

    Not recruiting

    4 1 1
    Investigated Drugs:
    • Ustekinumab
    • Guselkumab
    Belgium Croatia Czechia France Germany Hungary +7

  • Study of Fezolinetant for Hot Flashes in Women with Hormone Receptor-Positive Breast Cancer Receiving Hormone Therapy

    Not recruiting

    3 1
    Investigated Drugs:
    • Fezolinetant
    Czechia Denmark France Germany Hungary Italy +3

  • Study of Tucatinib, Trastuzumab, and Pertuzumab for Patients with Advanced or Metastatic HER2+ Breast Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Tucatinib
    • Pertuzumab
    • Trastuzumab
    Austria Belgium Czechia Finland France Germany +6

  • Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn’s Disease

    Not recruiting

    3 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Risankizumab
    Austria Belgium Bulgaria Croatia Czechia Denmark +16

  • Study of Capivasertib and Abiraterone for Patients with Metastatic Hormone-Sensitive Prostate Cancer with PTEN Deficiency

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Hormone-dependent prostate cancer
    Investigated Drugs:
    • Abiraterone Acetate
    • Capivasertib
    Belgium Bulgaria Czechia France Germany The Netherlands +3

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!